
    
      The study will assess multiple doses of atacicept vs. placebo on impact of renal function as
      measured by proteinuria. Safety, eGFR, serum immunoglobulins and gd-IgA1 will also be
      clinically assessed. The clinical study is comprised of a 36wk double-blind treatment period,
      followed by a 60wk open-label treatment period and a 12wk safety follow-up period.
    
  